Versartis, Inc. (NASDAQ:VSAR) saw a large growth in short interest during the month of September. As of September 29th, there was short interest totalling 2,451,635 shares, a growth of 68.8% from the September 15th total of 1,451,990 shares. Based on an average daily volume of 7,869,726 shares, the short-interest ratio is currently 0.3 days. Approximately 9.5% of the company’s stock are short sold.
In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.90% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of VSAR. First Quadrant L P CA bought a new stake in Versartis during the 2nd quarter worth about $155,000. Bank of America Corp DE boosted its stake in shares of Versartis by 46.3% in the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 3,001 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Versartis in the 2nd quarter valued at about $218,000. Numeric Investors LLC bought a new position in shares of Versartis in the 2nd quarter valued at about $246,000. Finally, Voya Investment Management LLC boosted its stake in shares of Versartis by 26.1% in the 2nd quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,094 shares during the last quarter. 78.24% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Versartis (VSAR) opened at 2.70 on Friday. Versartis has a 52 week low of $2.35 and a 52 week high of $24.00. The firm’s market capitalization is $96.06 million. The stock has a 50 day moving average of $12.32 and a 200-day moving average of $16.56.
Versartis (NASDAQ:VSAR) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.20). Analysts expect that Versartis will post ($3.61) earnings per share for the current year.
A number of equities research analysts recently weighed in on the stock. BidaskClub downgraded shares of Versartis from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. ValuEngine lowered shares of Versartis from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Cowen and Company reissued an “outperform” rating and set a $45.00 target price on shares of Versartis in a research note on Wednesday, August 23rd. Finally, Piper Jaffray Companies set a $26.00 target price on shares of Versartis and gave the company a “buy” rating in a research note on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $7.22.
COPYRIGHT VIOLATION NOTICE: “Versartis, Inc. (VSAR) Sees Large Increase in Short Interest” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/10/13/versartis-inc-vsar-sees-large-increase-in-short-interest.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
What are top analysts saying about Versartis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis Inc. and related companies.